Incidence of new stroke or new myocardial infarction or death at 39-month follow up in patients with diabetes mellitus, hypertension, or both treated with and without angiotensin-converting enzyme inhibitors or angiotensin receptor blockers

Gautham Ravipati, Wilbert S. Aronow, Chul Ahn, Rose M. Alappat, John A. McClung, Melvin B. Weiss

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

We investigated in 306 patients, mean age 57 ± 10 years, with diabetes mellitus (202 patients) or hypertension (179 patients), whether treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ARBs) reduced the incidence of new stroke or new myocardial infarction (MI) or death. At 39-month follow up, new stroke or new MI or death developed in 49 of 228 patients (21%) treated with ACE inhibitors or ARBs and in 33 of 78 patients (42%) treated without angiotensin-converting enzyme inhibitors or ARBs (P = 0.0001). Stepwise Cox regression analysis showed that significant independent predictors of the time to development of new stroke or new MI or death were 1) use of angiotensin-converting enzyme inhibitors or ARBs (risk ratio, 0.21), 2) diabetes (risk ratio, 4.01), 3) left ventricular hypertrophy (risk ratio, 6.71), 4) prior stroke (risk ratio,4.00), and 5) prior MI (risk ratio, 3.69).

Original languageEnglish (US)
Pages (from-to)2-4
Number of pages3
JournalAmerican Journal of Therapeutics
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2009

    Fingerprint

Keywords

  • Angiotensin receptor blocker
  • Angiotensin-converting enzyme inhibitor
  • Diabetes mellitus
  • Hypertension
  • Left ventricular hypertrophy
  • Myocardial infarction
  • Stroke

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this